BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,055 filers reported holding BAXTER INTL INC in Q2 2022. The put-call ratio across all filers is 1.57 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,276,844,690 | -17.6% | 60,329,748 | -0.5% | 0.06% | -15.2% |
| Q2 2023 | $2,762,979,047 | +12.1% | 60,644,843 | -0.2% | 0.07% | +4.8% |
| Q1 2023 | $2,465,837,899 | -2.7% | 60,794,820 | +22.3% | 0.06% | -8.7% |
| Q4 2022 | $2,533,481,689 | +14.2% | 49,705,350 | +20.7% | 0.07% | +6.2% |
| Q3 2022 | $2,217,545,000 | -15.2% | 41,172,408 | +1.1% | 0.06% | -12.2% |
| Q2 2022 | $2,616,406,000 | -15.5% | 40,734,962 | +2.0% | 0.07% | +1.4% |
| Q1 2022 | $3,096,020,000 | -7.5% | 39,928,028 | +2.4% | 0.07% | -3.9% |
| Q4 2021 | $3,346,069,000 | +6.8% | 38,980,284 | +0.1% | 0.08% | -2.6% |
| Q3 2021 | $3,133,212,000 | -0.1% | 38,955,772 | +0.0% | 0.08% | 0.0% |
| Q2 2021 | $3,134,835,000 | -4.9% | 38,942,060 | -0.4% | 0.08% | -12.4% |
| Q1 2021 | $3,296,645,000 | +4.9% | 39,087,559 | -0.2% | 0.09% | -2.2% |
| Q4 2020 | $3,143,695,000 | -0.8% | 39,178,644 | -0.6% | 0.09% | -13.3% |
| Q3 2020 | $3,168,200,000 | -8.0% | 39,395,678 | -1.5% | 0.10% | -13.9% |
| Q2 2020 | $3,442,332,000 | +5.1% | 39,980,621 | -0.9% | 0.12% | -12.9% |
| Q1 2020 | $3,274,491,000 | -0.4% | 40,331,212 | +2.6% | 0.14% | +25.0% |
| Q4 2019 | $3,286,402,000 | -3.5% | 39,301,623 | +1.0% | 0.11% | -11.1% |
| Q3 2019 | $3,404,633,000 | +11.8% | 38,923,432 | +4.7% | 0.13% | +9.6% |
| Q2 2019 | $3,044,150,000 | +0.1% | 37,169,097 | -0.6% | 0.12% | -3.4% |
| Q1 2019 | $3,041,846,000 | +24.0% | 37,410,479 | +0.4% | 0.12% | +8.2% |
| Q4 2018 | $2,452,356,000 | -12.6% | 37,258,535 | +2.4% | 0.11% | 0.0% |
| Q3 2018 | $2,805,993,000 | +5.8% | 36,398,931 | +1.3% | 0.11% | -0.9% |
| Q2 2018 | $2,652,978,000 | +13.3% | 35,928,733 | -0.2% | 0.11% | +8.8% |
| Q1 2018 | $2,342,055,000 | +0.5% | 36,009,441 | -0.1% | 0.10% | 0.0% |
| Q4 2017 | $2,330,856,000 | +7.1% | 36,059,037 | +4.0% | 0.10% | 0.0% |
| Q3 2017 | $2,175,671,000 | +6.2% | 34,672,054 | +2.5% | 0.10% | +1.0% |
| Q2 2017 | $2,048,069,000 | +20.5% | 33,830,016 | +3.2% | 0.10% | +16.1% |
| Q1 2017 | $1,699,228,000 | +20.0% | 32,765,687 | +2.6% | 0.09% | +10.1% |
| Q4 2016 | $1,415,732,000 | -5.2% | 31,928,979 | +1.8% | 0.08% | -10.2% |
| Q3 2016 | $1,492,733,000 | -3.1% | 31,359,938 | -8.0% | 0.09% | -8.3% |
| Q2 2016 | $1,540,832,000 | +14.5% | 34,074,147 | +4.0% | 0.10% | +10.3% |
| Q1 2016 | $1,345,707,000 | +9.9% | 32,758,241 | +2.1% | 0.09% | +6.1% |
| Q4 2015 | $1,224,329,000 | -50.9% | 32,092,496 | -56.6% | 0.08% | -11.8% |
| Q3 2015 | $2,491,391,000 | +15.8% | 73,952,598 | +140.4% | 0.09% | -35.9% |
| Q2 2015 | $2,151,171,000 | +3.8% | 30,761,766 | +1.7% | 0.14% | +2.8% |
| Q1 2015 | $2,071,947,000 | -2.6% | 30,247,393 | +4.2% | 0.14% | -7.8% |
| Q4 2014 | $2,127,654,000 | +6.1% | 29,030,611 | +3.9% | 0.15% | -1.9% |
| Q3 2014 | $2,005,570,000 | +1.5% | 27,944,406 | +2.3% | 0.16% | 0.0% |
| Q2 2014 | $1,975,621,000 | +0.1% | 27,325,319 | +1.8% | 0.16% | -6.0% |
| Q1 2014 | $1,974,609,000 | +8.5% | 26,836,221 | +2.6% | 0.17% | +3.8% |
| Q4 2013 | $1,820,044,000 | +7.3% | 26,168,857 | +1.4% | 0.16% | -3.6% |
| Q3 2013 | $1,695,782,000 | -5.8% | 25,814,924 | -0.7% | 0.17% | -12.2% |
| Q2 2013 | $1,800,900,000 | – | 25,998,260 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |